Target/Product
Primary Focus
Research
Preclinical (CTA/ IND enabling)
Clinical (Phase 1)
Milestone Date

Monotherapy in solid tumours (colorectal and pancreatic) followed by combination with anti-PD-1/PD-L1 in MSS mCRC

Phase 1 mono safety completion – H1 20

Phase 2 start – H2 20

Preclinical Development Candidate – H1 20

 

Entering Clinic – H1 21

Research

Partnered Pan-RAF inhibitor programme (ongoing milestones)

Target/Product
Primary Focus
Milestone Date

Monotherapy in solid tumours (colorectal and pancreatic) followed by combination with anti-PD-1/PD-L1 in MSS mCRC

Phase 1 mono safety completion – H1 20

Phase 2 start – H2 20

Research
Pre-clinical (CTA/ IND enabling)
Clinical (Phase 1)
Target/Product
Primary Focus
Milestone Date

Entering Clinic – 2021

Research
Pre-clinical (CTA/ IND enabling)
Clinical (Phase 1)
Target/Product
Primary Focus
Milestone Date

Preclinical Development Candidate – H1 20

 

Entering Clinic – H1 21

Research
Pre-clinical (CTA/ IND enabling)
Clinical (Phase 1)
Target/Product
Primary Focus
Milestone Date

Partnering Candidate

Research
Pre-clinical (CTA/ IND enabling)
Clinical (Phase 1)
Target/Product
Primary Focus
Milestone Date

Research

Partnered Pan-RAF inhibitor programme (ongoing milestones)

Research
Pre-clinical (CTA/ IND enabling)
Clinical (Phase 1)